The MaterniT21 test is a non-invasive prenatal screening (NIPS) that offers an early look at a developing baby’s genetic health. This screening analyzes cell-free DNA (cfDNA) found in the mother’s bloodstream to screen for chromosomal conditions like Trisomy 21, 18, and 13, and other sex chromosome abnormalities. Since the process involves complex molecular analysis, the timeline for receiving results extends beyond the initial blood draw. Understanding this timeline is important for managing expectations during the waiting period.
The Standard MaterniT21 Result Timeline
The typical turnaround time for MaterniT21 Plus results is between three and five calendar days after the sample has arrived at the laboratory facility. This timeframe begins once the sample is logged in at the testing laboratory, not on the day the blood is collected at the doctor’s office or clinic.
The standard timeline is an average, and some patients may receive their results sooner. For certain expanded panels, the reported turnaround can be as fast as 72 hours. Patients should confirm the expected window with their healthcare provider, as this average depends on efficient logistics and smooth laboratory processing.
The Laboratory Processing Steps
Once the blood sample arrives at the specialized facility, it first undergoes accessioning, where it is logged into the system and assigned a unique identifier. The biological material is then prepared for analysis by purifying circulating cell-free DNA from the maternal plasma. This step separates the tiny fragments of genetic material, including both maternal and placental DNA, from the rest of the blood components.
The isolated cfDNA is then converted into a genomic library for next-generation sequencing (NGS). Bioinformatic analysis interprets this data to quantify the amount of DNA from each chromosome, looking for excesses or deficiencies that may indicate an aneuploidy. Finally, the results undergo a quality control review before being released as a final report.
Variables That Can Affect the Wait Time
Several factors can extend the total time between the blood draw and receiving the final results. The most common cause of delay is the need for a redraw if the initial sample has insufficient fetal fraction. Fetal fraction is the percentage of the baby’s DNA in the mother’s blood, and a minimum threshold is required for accurate analysis. If the fetal fraction is too low, the laboratory cannot issue a reliable result and will request a repeat blood draw, adding several days or even weeks to the overall timeline.
Logistical issues, such as shipping delays from the clinic to the central testing laboratory, can also add days to the process, especially before a weekend or holiday. Internal laboratory factors, including a high volume of samples or technical issues, may also cause minor holdups. The average interval between the first and second draw is about two weeks, significantly lengthening the waiting period.
Receiving and Discussing Your Results
After the laboratory completes processing, the final MaterniT21 report is digitally transmitted to the healthcare provider who ordered the test. The ordering physician’s office or a genetic counselor is responsible for contacting the patient to communicate and discuss the findings. Some patients may also access their results directly through a secure patient portal, depending on the healthcare system’s policies.
Regardless of the findings, a follow-up discussion with a professional is necessary. The provider will explain the test’s results, including the fetal fraction, and address any questions. If the screening indicates a higher risk, the discussion will focus on potential next steps, such as further diagnostic testing or consultation with a specialist.